2012年までの消化器疾患市場動向

Abstract

Gastrointestinal (GI) disorders are set to affect over 250 million people in the seven largest pharma markets, by 2012. As generations of people become more obese and consume increasingly poor diets then so too will the number of people suffering from these disorders rise.

At present, the pharmaceutical prescription market to treat GI disorders market is valued at just over $20 billion, reflecting that it is one of the largest and most important therapeutic areas in the pharmaceutical industry. Visiongain has just produced a business intelligence report, Gastrointestinal Disorders 2007-2012, which addresses the state of this market, and assesses how it will develop in the future. Are you involved in this market area? Will the future of this market affect your business?

AstraZeneca' s Nexium is currently the most successful GI drug available in the market, based on sales revenues totaling more than $6 billion. What is the future for Nexium? How will its impact shape the GI market? Will other GI drugs reach blockbuster status? If so, which ones? Find out in this vital report.

Another example of change in the GI market is the withdrawal of Novartis' s from the US market, due to safety and efficacy issues. What effects will this have on the other GI drugs? How will this affect the overall GI market? What does the future hold for Novartis and Zelnorm? These are all crucial questions that need answers, which can be found by buying this visiongain report.

Visiongain' s World Gastrointestinal Disorders report includes three major classes of product which visiongain believes will extensively occupy the GI market. These are:

• Proton Pump Inhibitors (PPIs)
• Histamine H2 Receptor Antagonists
• Other Leading GI agents

Which new drugs will be marketed? Which drugs will have the most impact on the market? Most importantly, what are the future prospects of the GI market?

The following crucial aspects of the GI market are discussed:

• The current world GI market
• SWOT Analysis of the GI market
• Revenue Forecasts for all the drugs analysed 2007-2012
• Market Activity
• Geographical breakdown of GI market
• Potential treatment population forecasted to 2012 for major leading global markets
• Discussion on comparative pricing of the major GI drugs
• Analysing the major generic/substitute products
• Detailed information on pipeline products
• Discussion on possible future strategies in GI market

Why You Must Buy This Report:

This 180+ paged report features 47 figures which includes graphs and charts, 28 tables, insight, and include the latest developments in the gastrointestinal market with up-to-date analysis.

This report will give you the understanding you require to gain that competitive edge in the GI market. This large revenue producing therapeutic area is in the top ten of the largest earning revenues in the pharma industry. Therefore, it is vital that the latest gastrointestinal report is brought without fail.

The revenue forecasts generated in this report are highly accurate and are determined by the market and its future prospects in terms of patent protection, generic competition, life-cycle management, licensing agreements and market activity. The forecast runs up to 2012. Therefore it gives your company sound understanding of how GI drug will behave up until that time.

Key questions that this report answers:

• What are the most influential GI disorders and their impacts?
• Which drugs are dominating their classes in the GI market?
• What is the revenue potential in 2012 for these drugs?
• What market activity is occurring? (What are pharma companies doing?) What is the potential population treatment in the major global markets up to 2012?
• Which is the status of the GI pipeline?

Unique benefits to you when you order this report:

• Immediate access through our exclusive Reading Room
• You can access your report whichever country you are in without using hard drive space
• Primary research throughout. You will not find this information anywhere else
• Report stored in your reading room for ever
• Full searchable report when you buy the company or corporate editions
• Copies can be printed off for offline reading
• Packed with charts, analysis, figures, graphs and tables

Table of Contents

Executive Summary: Gastrointestinal Treatments Constitute A Considerable Increase in the Market

Chapter 2: Introduction to Gastrointestinal Disorders

• 2.1 Gl Conditions are Widespread
  • 2.1.1 Gl Disorders have a Considerable Impact on Society
  • 2.1.2 GI Drugs Represented in the Top 100 Best Selling Prescription Drugs
• 2.2 Gastroesophageal Reflux Disease
  • 2.2.1 What is Gastroesophageal Reflux Disease (GERD)?
  • 2.2.2 Causes of GERD
  • 2.2.3 Symptoms of the Condition
  • 2.2.4 Identifying The GERD
  • 2.2.5 Incidence of GERD
  • 2.2.6 Economic Impact of GERD
• 2.3 Inflammatory Bowel Disease (Crohn' s Disease and Ulcerative Colitis)
  • 2.3.1 What is Crohn' s Disease?
  • 2.3.2 Causes of Crohn' s Disease
  • 2.3.3 Symptoms of Crohn' s Disease
  • 2.3.4 Identifying the Condition
  • 2.3.5 What is Ulcerative Colitis?
  • 2.3.6 Causes of Ulcerative Colitis
  • 2.3.7 Symptoms of Ulcerative Colitis
  • 2.3.8 Identifying Ulcerative Colitis
  • 2.3.9 Worldwide Occurrence of IBD - Crohn' s Disease Is Increasing Throughout the World
  • 2.3.10 Economic Burden of IBD
• 2.4 Irritable Bowel Syndrome
  • 2.4.1 Synopsis of Irritable Bowel Syndrome
  • 2.4.2 Causes of Irritable Bowel Syndrome
  • 2.4.3 Symptoms of Irritable Bowel Syndrome
  • 2.4.4 Identifying Irritable Bowel Syndrome
  • 2.4.5 Prevalence of Irritable Bowel Syndrome
  • 2.4.6 The Cost of Irritable Bowel Syndrome
• 2.5 Peptic Ulcer Disease
  • 2.5.1 What is Peptic Ulcer Disease?
  • 2.5.2 Causes of Peptic Ulcer Disease
  • 2.5.3 Symptoms of the Condition
  • 2.5.4 Diagnosis of Gastric Ulcers
  • 2.5.5 Helicobacter Pylori is often the Presumed Causative Agent of Ulcers
  • 2.5.6 Demographic Prevalence of Peptic Ulcers
  • 2.5.7 Economic Impact of the Condition
• 2.6 A Summary of the Gl Drug Market
• 2.7 Histamine H2 Receptor Antagonists for the Treatment of Gl Disorders
  • 2.7.1 Histamine H2 Receptor Antagonists Continues to Maintain a Market Presence Among Leading GI Drugs
  • 2.7.2 Forms of Action for Histamine H2 Receptor Antagonists Inhibitors
• 2.8 Proton Pump Inhibitors for the Treatment of Gl Disorders
  • 2.8.1 PPIs are a Newer Class of Medication ? Which Lead the GI Market
  • 2.8.2 PPIs Modes of Action
• 2.9 Other Agents for Treating Gl Disorders
  • 2.9.1 OTC Antacids
  • 2.9.2 Sucralfate
  • 2.9.3 Bismuth Subsalicylate
  • 2.9.4 Aminosalicylic Acid (5-ASA) Compounds
  • 2.9.5 Prokinetic Agents
  • 2.9.6 Corticosteroids
  • 2.9.7 Mesalamine
  • 2.9.8 Sulfasalazine
  • 2.9.9 Infliximab
  • 2.9.10 Antibiotics

Chapter 3: The World Gastrointestinal Market, 2007-2012

• 3.1 Altering Dynamics will Cause an Overall Decline in Revenues in the GI Market Between 2007-2012
• 3.2 In 2010 AstraZeneca will Remain the Leading Company in the GI Market
• 3.3 Shire' s Focused Strategy
  • 3.3.1 Lialda (mesalamine) with MMX Technology
• 3.4 Given Imaging Announces 500,000th Pill Cam SB Capsule Milestone
• 3.5 Salix in a $55 Million Deal With Merck
• 3.6 Sutent Allowed in Great Britain as Gastrointestinal Cancer Drug
• 3.7 New Crohn' s disease treatment Humira Promises to Reduce Symptoms
• 3.8 PPIs Will Continue Their Domination of the Gl Market
• 3.9 Blockbuster Revenues Can Still be Accomplished During 2007-2012
• 3.10 OTC GI Products to Account for Increased Market Share
• 3.11 Generics Offer Threat to Branded Market Share

Chapter 4: The World Market for Proton Pump Inhibitors, 2007-2012

• 4.1 PPIs -Under Pressure Due to Increasing Competitive Forces
  • 4.1.1 Patent Expirations Will Influence the Size of the Overall Market
  • 4.1.2 OTC Prevacid and Generics Will Continue to Play a Part in the GI Market
• 4.2 Nexium Will Continue to Decline in Revenues, Which will Affect the Overall GI Market
  • 4.2.1 AstraZeneca Realise Increasing Competition in GI market
  • 4.2.2 AstraZeneca' s Conversion Strategy Even More Crucial Than Before
  • 4.2.3 AstraZeneca Litigated Against Ranbaxy Laboratories Regarding Patent Infringement on Nexium
  • 4.2.4 AstraZeneca' s Blockbuster Drugs Coming Under Severe Pressure
    • 4.2.4.1 Dr Reddy' s Submitted ANDA to the FDA for Nexium
    • 4.2.4.2 IVAX Pharmaceuticals Submitted ANDA for Nexium
    • 4.2.4.3 Dexcel Pharma Submitted ANDA for Prilosec
  • 4.2.5 AstraZeneca Lost an Important Contract to Supply Nexium
  • 4.2.6 The Promotion and Marketing of Nexium Plagued by Legal Challenges
    • 4.2.6.1 Examples of Action Against AstraZeneca
  • 4.2.7 Nexium I.V. Approved as a Short-Term Treatment for GERD
• 4.3 Prevacid - Another PPI That Faces Deteriorating Revenues
  • 4.3.1 TAP Pharmaceutical: A Joint Venture Between Abbott and Takeda
  • 4.3.2 Abbott Admits Increased Competition for Prevacid
  • 4.3.3 TAP Licenses Prevacid Intellectual Property Rights to Novartis
  • 4.3.4 TAP Reassess Expenditure on DTC Advertising for Prevacid
  • 4.3.5 FDA Extended Approval for Prevacid Delayed Release Orally Disintegrating Tablets
  • 4.3.6 Prevacid Receives Extended Paediatric Approval from FDA
  • 4.3.7 The FDA Approved Prevacid I.V. For Erosive Oesophagitis in Hospitalised Patients
• 4.4 Prilosec/Losec - AstraZeneca' s Strategy Spot On
  • 4.4.1 Generics Will Continue to Increasingly Threaten Prilosec/Losec
  • 4.4.2 AstraZeneca Faced EU Patent Abuse Charges Concerning Losec
• 4.5 Protonix Facing Patent Expiry Later This Decade
  • 4.5.1 Protonix will Decline in Revenues After Patent Expiration
  • 4.5.2 Protonix Benefited from Early Approval for Pathological Hypersecretory Conditions
  • 4.5.3 Teva Pharmaceuticals Received Tentative Approval for Generic Protonix
• 4.6 Pantozol will Follow the Same Suite as Protonix
  • 4.6.1 Wyeth Acts as a Partner for Sales of Pantoprazole in the US
  • 4.6.2 Patent Protection for Pantoprazole Extended
  • 4.6.3 Altana Challenged State' s Decision on Price Reference
• 4.7 Takepron will Experience Similar Decline in Revenue
  • 4.7.1 Takeda Developed Lansoprazole
  • 4.7.2 Lansoprazole (Takepron) for Nonerosive Oesophagitis in Japan
  • 4.7.3 Takeda Announced Launch of Takepron I.V. in Japan
• 4.8 Aciphex/Pariet will Go Against the PPI Trend and Continue to Grow in Revenue
  • 4.8.1 Eisai' s Commercial Arrangement with Johnson & Johnson for Aciphex/Pariet
  • 4.8.2 Mylan: FDA Gives Tentative OK to Generic Aciphex
  • 4.8.3 Dr Reddy' s Expects Verdict on Aciphex Very Soon
  • 4.8.4 Eisai Applies for New Indication of Non-Erosive Gastro-Oesophageal Reflux Disease for Pariet in Japan
  • 4.8.5 Eisai Receives Approval for a New Indication for Pariet in Japan for Eradicating H. Pylori
  • 4.8.6 Eisai Receives Decisions of Summary Judgment Motion in US Legal Action Over Aciphex ANDA Filing
  • 4.8.7 New Production Facilities for Aciphex/Pariet Incorporate Latest Technology to Achieve Cost Savings
• 4.9 Zoton' s Loss of Patent Protection will Hurt its Revenues
  • 4.9.1 Zoton Capsules Discontinued in the UK
• 4.10 The Market for PPIs: Summary and Conclusions

Chapter 5: The World Market for Histamine H2 Receptor Antagonists and Other Leading Gastrointestinal Drugs, 2007-2012

• 5.1 H2 Antagonists will Suffer Declining Revenues From 2007-2012
  • 5.1.1 H2 Antagonists are a Mature Drug Class
  • 5.1.2 Gaster and Zantac are Available in OTC Formulations
• 5.2 Gaster Faces Continuing Decline
  • 5.2.1 Prescription Gaster will Continue to Lose Sales to OTC Formulation (Gaster 10)
  • 5.2.2 Prescription Sales of Gaster to Show a Further Decline in Revenues
• 5.3 Zantac Brand in Decline
  • 5.3.1 Sales of Zantac Are Declining in All Regions
  • 5.3.2 Par Pharmaceuticals Signs Supply, Distribution Agreement with GSK for Generic Zantac Syrup
  • 5.3.3 Boehringer Ingelheim Pharmaceuticals Announced Agreement to Acquire Zantac from Johnson & Johnson and the Pfizer Consumer Healthcare Business
• 5.4 Other Leading GI Agents will Show Growth in Revenue
• 5.5 Zelnorm/Zelman
  • 5.5.1 Novartis Halts Zelnrom Sales
  • 5.5.2 Zelnorm Sales Plunge - What Next?
  • 5.5.3 Vioxx - A Similar Case
  • 5.5.4 Zelnorm/Zelmac is Currently Being Developed for Other Important GI Indications - will they be Effected?
• 5.6 Gasmotin - Steady Growth
  • 5.6.1 Dianippon Pharmaceuticals are Striving to Maintain Growth of Gasmotin
  • 5.6.2 Dainippon Pharma and Eisai Sign Licensing Agreement for Gasmotin
  • 5.6.3 Gasmotin Discontinued for New Indication
• 5.7 Nauzelin will Experience Falling Revenues
• 5.8 Canasa/Salofalk will Also Produce Steady Growth
  • 5.8.1 Axcan Pharma Specialises in Gastroenterology
• 5.9 Entocort will Generate Stable Growth
  • 5.9.1 AstraZeneca' s Entocort a Specialised Drug
  • 5.9.2 AstraZeneca' s Agreement With Prometheus Laboratories Key
    • 5.9.2.1 Entocort' s Net Sales Increase Almost Three-Fold in the US
• 5.10 The Market for H2 antagonists and Other Leading GI Agents: Summary and Conclusions

Chapter 6: An Examination of Factors That Influence the Gastrointestinal Market

• 6.1 SWOT Analysis of the Prescription Gl Market
• 6.2 Changes in the Prescription Gl Market Create Opportunities
• 6.3 GERD Symptoms are Increasingly Common - Opportunities Lie for Expanding the Treatment Population
• 6.4 An Ageing Population will Asist the GI
• 6.5 Risk Reduction of NSAID-Associated Stomach Ulcers Illustrate an Opportunity for PPIs
• 6.6 What Unmet Needs and Potential Solutions Exist in the Gl Market?
  • 6.6.1 How Effective are PPIs and H2 Antagonists?
  • 6.6.2 Combination Therapy May have Commercial Potential
  • 6.6.3 5HT3 and 5HT4 Agents May Improve Certain Treatments
• 6.7 Losses of Patent Protection will be the Main Barrier in the Prescription Gl Market
• 6.8 To What Extent is the Gl Market Threatened by Generic Substitutes?
  • 6.8.1 Increasing Generic Competition for Leading GI Drugs
  • 6.8.2 Generic Omeprazole - A Case Study In Generic Erosion of Branded Sales
  • 6.8.3 A Warning of the Generic Threat to Branded Gl Drugs
• 6.9 High Prices of Branded PPIs Encourage Use of Generics and OTC Formulations
• 6.10 Prilosec OTC will Continue to be Influential in the GI Market
• 6.11 DTC Advertising has Affected the GI Market - Companies are Modifying Advertising Strategies
  • 6.11.1 AstraZeneca' s Problems Over its Marketing of Nexium

Chapter 7: Geographical Breakdown of the World Gastrointestinal Market

• 7.1 The US will Lead the Global Market in 2012
• 7.2 The US Market Generates High Revenues and Prescription Numbers
• 7.3 A Serious Global Health Problem - With Many Sufferers Currently Untreated or Under-treated
• 7.4 Conclusions: There is Scope To Expand the Treatment of Gl Disorders Globally

Chapter 8: Pipeline Drugs for Gastrointestinal Conditions

• 8.1 The GI Market will Become Increasingly Competitive For New Drugs - More Onus on Distribution Channels and Commercial Alliances
• 8.2 Agents in Pre-Clinical Development
• 8.3 Agents in Phase I of Clinical Development
• 8.4 Agents in Phase II of Clinical Development
  • 8.4.1 The Potassium-Competitive Acid Blockers
  • 8.4.2 Acid-Pump Antagonists
• 8.5 Agents in Phase III of Clinical Development
  • 8.5.1 Axcan' s Itax to Treat Functional Dyspepsia -a Mere Disappointment
• 8.6 Agents for Which Final Regulatory Approval is Pending
• 8.7 An Evaluation of Pipeline Developments in the Gl Market

Chapter 9: Conclusions: Gastrointestinal Disorders Constitute a Large Drugs Market That Is Facing Increasing Pressures

• 9.1 Changing Dynamics will Cause Overall Decline of Revenues in the Prescription Gl Market
• 9.2 Zelnorm' s Halt will have Adverse Effects
• 9.3 The Pipeline for Gl Drugs Looks Promising
• 9.4 Continuing Investment is Required
• 9.5 GI Strategy Needs to be Revised

List of Figures

• Figure 1.1 World Revenues ($m) for the Classes of Leading Gl Drugs, 2007-2012
• Figure 1.2 World Revenues ($m) for the Leading Gl Drugs Combined, 2007-2012
• Figure 1.3 Forecast Revenues ($m) for Proton Pump Inhibitors and H2 Antagonists (Combined) by Country, 2012
• Figure 2.1 Prevalence Rates of IBD Worldwide in 2007
• Figure 3.1 World Revenues ($m) for the Leading GI Drugs (Combined), 2007-2012
• Figure 3.2 World Revenues ($m) for the Classes of Leading Gl Drugs, 2007-2012
• Figure 3.3 World Market Share (%) for Gl Drugs by Class, 2007
• Figure 3.4 World Market Share (%) for Gl Drugs by Class, 2012
• Figure 3.5 Changes ($m) in World Revenue for the Classes of Gl Drugs, 2007-2012
• Figure 3.6 Changes (%) in World Revenues for the Classes of Gl Drug, 2007-2012
• Figure 4.1 World Revenue ($m) for All PPIs, 2007-2012
• Figure 4.2 World Revenues ($m) for PPIs By Drug, 2007- 2012
• Figure 4.3 World Market Share (%) for PPIs, 2007
• Figure 4.4 World Market Share (%) for PPIs, 2012
• Figure 4.5 Revenues ($m) for PPIs, Comparing 2007 and 2012
• Figure 4.6 World Nexium Revenues ($bn), 2007-2012
• Figure 4.7 World Prevacid (TAP) Revenues ($m), 2007- 2012
• Figure 4.8 World Prilosec/Losec Revenues ($bn), 2007- 2012
• Figure 4.9 World Protonix Revenues ($bn), 2007-2012
• Figure 4.10 World Pantozol Revenues ($bn), 2007-2012
• Figure 4.11 World Takepron Revenues ($bn), 2007-2012
• Figure 4.12 World Aciphex/Pariet Revenues ($bn), 2007- 2012
• Figure 4.13 World Zoton Revenues ($m), 2007-2012
• Figure 5.1 World Revenue ($m) for Histamine H2 Receptor Antagonists, 2007-2012
• Figure 5.2 World Revenues ($m) for Histamine H2 Receptor Antagonists by Drug, 2007-2012
• Figure 5.3 World Market Share (%) for Histamine H2 Receptor Antagonists, 2007
• Figure 5.4 World Market Share (%) for Histamine H2 Receptor Antagonists, 2012
• Figure 5.5 Revenues ($m) for Histamine H2 Receptor Antagonists, 2007 and 2012 Compared
• Figure 5.6 World Gaster Revenues ($m), 2007-2012
• Figure 5.7 World Zantac Revenues ($m), 2007-2012
• Figure 5.8 World Revenue ($m) for Other Gl Agents, 2007- 2012
• Figure 5.9 World Revenues ($m) for Other Gl Agents by Drug, 2007-2012
• Figure 5.10 World Market Share (%) for Other Gl Agents, 2007
• Figure 5.11 World Market Share (%) for Other Gl Agents, 2012
• Figure 5.12 Revenues ($m) for Other Gl Agents, Comparing 2007 and 2012
• Figure 5.13 World Zelnorm/Zelmac Revenues ($m), 2007- 2012
• Figure 5.14 World Gasmotin Revenues ($m), 2007-2012
• Figure 5.15 World Nauzelin Revenues ($m), 2007-2012
• Figure 5.16 World Canasa Revenues ($m), 2007-2012
• Figure 5.17 World Salofalk Revenue ($m), 2007-2012
• Figure 5.18 World Entocort Revenues ($m), 2007-2012
• Figure 5.19 US Entocort Net Sales $m
• Figure 6.1 Generic Revenues ($ thousands) for Selected GI Agents in the US, 2006
• Figure 6.2 Revenues ($m) of AstraZeneca' s Prilosec and KUDCo' s Generic Omeprazole, 2003-2005
• Figure 6.3 Average Monthly Costs ($) of Using PPIs (20 mg) in the US, 2006
• Figure 7.1 Potential Treatment Populations for PPIs and H2 Antagonists (Combined) by Country, 2012
• Figure 7.2 Forecast Revenues ($m) For PPIs and H2 Antagonists (Combined) by Country, 2012
• Figure 7.3 US Revenues for Leading Prescription GI Drugs ($m), 2005

List of Tables

• Table 1.1 World Revenues ($m) for the Leading Gastrointestinal Drugs, by Class, 2007-2012
• Table 2.1 Cost of GI Conditions to US Healthcare
• Table 2.2 Prevalence of IBD Worldwide in 2007
• Table 2.3 Indications for Leading Gastrointestinal Drugs
• Table 2.4 Leading Histamine H2 Receptor Antagonists to Treat Gl Disorders
• Table 2.5 Leading Proton-Pump Inhibitors to Treat Gastrointestinal Disorders
• Table 2.6 Other Leading Agents for Treating Gastrointestinal Disorders
• Table 3.1 Blockbuster Drugs in the World Gastrointestinal Market
• Table 3.2 World Revenues ($m) for the Leading Gl Drugs, by Class, 2007-2012
• Table 3.3 World Market Revenue ($m) and Market Share (%) for Leading GI Drugs by Class, 2012
• Table 3.4 Blockbuster Drugs in the World Gl Market, 2012
• Table 4.1 World Revenues for PPI Market $m, 2007-2012
• Table 4.2 Patent Expiry for PPIs, 2007
• Table 4.3 World Market Shares (%) for Proton Pump Inhibitors, 2007 and 2012
• Table 5.1 World Revenues for Histamine H2 Receptor Antagonists, 2007-2012
• Table 5.2 Patent Expiry for Histamine H2 Receptor Antagonists, 2007
• Table 5.3 World Revenues for Other Gl Agents $m, 2007- 2012
• Table 5.4 World Market Shares (%) for Histamine H2 Receptor Antagonists, 2007 and 2012
• Table 5.5 World Market Shares (%) for Other Gastrointestinal Agents, 2007 and 2012
• Table 6.1 A SWOT Analysis of GI Market, 2007-2012
• Table 6.2 Leading GI Brands Due to Lose Patent Protection During the Forecast Period 2007- 2012
• Table 6.3 Generic Substitutes for Leading GI Prescription Drugs, 2007
• Table 6.4 The PPI Cost Comparison in the US
• Table 6.5 Some Leading OTC Drugs for Heartburn Associated With Acid Reflux In Adults
• Table 7.1 Potential Treatment Populations for PPIs and H2 Antagonists (Combined) by Country, 2012
• Table 7.2 Forecast Revenues ($m) For PPIs and H2 Antagonists (Combined) by Country, 2012
• Table 9.1 Drivers and Restraints for the GI market
• Table 9.2 World Market Revenue ($m) and Market Share (%) for Leading Gastrointestinal Drugs by Class, 2012

Organisations Listed

• Abbott Laboratories
• Altana
• Apotex Corporation
• ARigen
• Astellas Pharma
• AstraZeneca
• Axcan Pharma
• Bentley Pharmaceuticals
• Berlex Inc
• Boehringer Ingelheim Pharmaceuticals
• Dainippon Pharmaceutical
• Dainippon Sumitomo Pharma Co
• Dexcel Pharma Technologies
• Dr Reddy' s Laboratories
• Eisai
• Eon Labs Manufacturing
• Gedeon Richter
• Genzyme Corp
• Given Imaging
• GlaxoSmithKline
• Impax Laboratories
• Ivax Pharmaceuticals
• Janssen Pharmaceutica
• Johnson & Johnson
• Kissei
• KUDCo
• Kyowa Hakko Kogyo
• Lek Pharmaceutical and Chemical Company
• Lek Services USA
• Merck & Co
• Merck KGaA
• Mylan Pharmaceuticals
• Napo Pharmaceutical
• New River Pharmaceuticals
• Novartis
• NPS Pharmaceuticals
• Otsuka America Pharmaceutical
• Pain Therapeutics
• Par Pharma
• Pfizer
• Prudential
• Proctor & Gamble
• Progenics Pharmaceuticals
• Prometheus Laboratories
• Ranbaxy Laboratories
• Ratiopharm
• Salix Pharmaceuticals
• Sandoz
• Santarus
• Sankyo
• Schering AG
• Schwarz Pharma
• Shire US Inc
• Solvay Pharmaceuticals
• Stada Servier
• Sucampo Pharmaceuticals
• Sumitomo Pharmaceuticals Co
• Takeda Chemical Industries
• Takeda Pharmaceutical
• TAP Pharmaceutical Products
• Teva Pharmaceuticals
• Teva USA
• UCB Pharma
• Western Pharma
• Wyeth